Cartesian Therapeutics
RNAC
103 hedge funds and large institutions have $217M invested in Cartesian Therapeutics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 14 closing their positions.
730% more call options, than puts
Call options by funds: $2.73M | Put options by funds: $329K
16% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 31
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
2% more funds holding
Funds holding: 101 → 103 (+2)
0.04% less ownership
Funds ownership: 1.54% → 1.5% (-0.04%)
1% less capital invested
Capital invested by funds: $219M → $217M (-$2.26M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.1M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$2.05M |
| 3 |
BlackRock
New York
|
+$1.11M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.02M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$955K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$5.53M |
| 2 |
CA
Cetera Advisors
Denver,
Colorado
|
-$4.62M |
| 3 |
Millennium Management
New York
|
-$3.63M |
| 4 |
SG Americas Securities
New York
|
-$2.04M |
| 5 |
Two Sigma Investments
New York
|
-$1.63M |
RNAC Hedge Fund Activity: Q3 2021 in Review
103 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2021, worth a combined $217M — down 1% from $219M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RNAC positions and 14 closed out — a net gain of 2 holders — while 36 added to existing stakes and 31 trimmed.
The largest buyer was State Street, adding an estimated $12.1M. The largest seller was BVF Inc, cutting an estimated $5.53M.
- 103 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2021, up from 101 in Q2 2021.
- Funds reported $217M of Cartesian Therapeutics stock for Q3 2021, down 1% quarter-over-quarter.
- 16 funds opened new Cartesian Therapeutics positions in Q3 2021 and 14 closed out, a net change of +2 holders.
- The largest Cartesian Therapeutics buyer in Q3 2021 was State Street, an estimated $12.1M added.
- The largest Cartesian Therapeutics seller in Q3 2021 was BVF Inc, an estimated $5.53M sold.
Based on aggregated 13F filings for Q3 2021.